Notable News Buzz: KB Home (NYSE:KBH), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

On Friday, Shares of KB Home (NYSE:KBH), added 1.59 % and closed at $15.35 in the last trading session. The last trading range of the stock ranges between $15.10 and $15.44. KB Home (KBH) recently declared that Randy Carpenter has been named president of its Colorado division. In this role, Carpenter is responsible for implementing the division’s growth strategies and overseeing its operations, counting land acquisitions, construction, customer service, purchasing, studio, sales, marketing, and development.

“We are proud to promote Randy to president of our Colorado division,” said Matt Mandino, regional president of KB Home. “Since 2012, Randy has played a key role in the team’s sales and marketing efforts and delivered outstanding results, while also significantly contributing to KB Home’s sales-related programs on a company-wide basis. With his managerial experience and thorough knowledge of our business, we believe Randy’s leadership will further extend KB Home’s history of success in Colorado.”

Carpenter has 23 years of real estate and homebuilding experience at public and private homebuilders. His background includes general real estate practice, construction, consulting, and serving for more than 13 years as a sales and marketing executive with local, regional and national firms. He was recently promoted to senior vice president of KB Home’s Colorado division, in charge of all operational functions, before being named president.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), dropped -3.13% and closed at $28.81 in the last trading session. The last trading range of the stock ranges between $28.33 and $29.93. The company’s Market capitalization is $3.38 Billion with the total Outstanding Shares of 121.11 million. ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, recently declared its unaudited financial results for the third quarter ended September 30, 2016.

“We are very happy with the launch and are gratified by the positive feedback we have received from physicians, patients, and caregivers on NUPLAZID (pimavanserin),” said Steve Davis, ACADIA’s President and Chief Executive Officer. “We saw solid month-over-month prescription growth, stated raised payor coverage, and continued to expand awareness of NUPLAZID among movement disorder specialists, neurologists, and psychiatrists.”

Leave a Reply

Your email address will not be published. Required fields are marked *